You are here: Industry Insights > Novo Nordisk

News List

Recipients of the Novo Nordisk Prize played major role in the research and development of the COVID-19 mRNA vaccine prnewswire
September 28, 2021
Scientists receive prestigious prize from the Novo Nordisk Foundation in recognition of their decades-long tremendous research and development efforts and impact on people's lives and society.
Prothena and Novo Nordisk Agreement for ATTR Amyloidosis Program americanpharmaceuticalreview
July 13, 2021
Novo Nordisk A/S has acquired Prothena Corporation’s clinical-stage antibody PRX004 and broader ATTR amyloidosis program.
Investigational 2 mg Dose of Ozempic (semaglutide) Injection Demonstrates Superior Reductions in Blood Sugar vs Ozempic 1 mg in Adults With Type 2 Diabetes in a Phase 3 Trial firstwordpharma
June 28, 2021
Novo Nordisk today presented data showing that an investigational 2 mg dose of Ozempic® (semaglutide) injection provided statistically significant and superior reductions in blood sugar (A1C) compared with Ozempic®1 mg.
Lumen Bioscience and Novo Nordisk Collaborate on Research of Biologics for Cardiometabolic Disease americanpharmaceuticalreview
June 18, 2021
Lumen Bioscience, a clinical-stage biopharma company developing biologic drugs for prevalent diseases, will collaborate with Novo Nordisk.
Lumen Bioscience, Novo Nordisk Enter Metabolic Research Pact contractpharma
June 17, 2021
Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologics for highly prevalent diseases, has entered into a research collaboration with Novo Nordisk to evaluate Lumen's drug development and manufacturing platform in ...
Novo Nordisk’s ziltivekimab hits primary endpoint in CKD trial pharmatimes
May 18, 2021
Novo Nordisk’s investigational interleukin-6 (IL-6) inhibitor ziltivekimab met the primary endpoint in a Phase II trial in people with advanced chronic kidney disease (CKD) and elevated high-sensitivity C-reactive protein (hsCRP), representing high ...
Novo Nordisk’s weight loss drug semaglutide found to improve wellbeing pharmatimes
May 14, 2021
New results from a Phase IIIa study have demonstrated that Novo Nordisk’s weight loss drug semaglutide improved physical function and wellbeing among people with obesity.
Novo Nordisk reports increased Q1 2021 profit pharmaceutical-technology
May 07, 2021
The operating profit of Novo Nordisk decreased by 8% in local currency from kr16.3bn ($2.63bn) in last year’s quarter to kr14.9bn ($2.4bn) this quarter but increased by 3% at constant exchange rates (CER).
Novo Nordisk plans study of oral semaglutide in obesity pharmatimes
April 23, 2021
Novo Nordisk is planning to initiate a Phase IIIa study of oral semaglutide in obesity, the Danish pharma company announced 21st.
Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years prnasia
March 29, 2021
Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment of obesity in adolescents aged 12–17 years.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page